Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
Medscape11h
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Medscape5d
GLP-1 RAs Unlikely to Increase Suicide Risk
Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...
MPR11d
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...
Renal & Urology News12d
AAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize Complications
Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. (HealthDay News) — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment ...